Welcome to our dedicated page for PROPANC BIOPHARMA news (Ticker: $PPCB), a resource for investors and traders seeking the latest updates and insights on PROPANC BIOPHARMA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PROPANC BIOPHARMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PROPANC BIOPHARMA's position in the market.
Rhea-AI Summary
Propanc Biopharma receives a certificate of grant for the 'Composition of Proenzymes for Cancer Treatment' patent from the European Patent Office. The patent covers lower dosage ratios of the two proenzymes in the PRP formulation, expanding the Company's IP portfolio to 94 patents filed globally. This development is important as the Company progresses into early-stage clinical trials, aiming to establish itself as a leader in cancer treatment innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
-
Rhea-AI Summary
Propanc Biopharma, Inc. CEO, Mr. James Nathanielsz, discusses the competitive advantage of the company in revolutionizing cancer treatment on a podcast with Joel Block. Key points include global financing strategy, benefits of being a public company, ethical communication, patient-centric drug development, and science-based differentiation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
-
Rhea-AI Summary
Propanc Biopharma, Inc. (PPCB) announces remarkable results from a compassionate use study on their proenzyme therapy for advanced metastatic cancers. The study showed a 41.3% survival rate longer than expected, with no severe adverse events. Management will discuss these results and plans for advancing their lead asset in a corporate update call on March 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
Rhea-AI Summary
Propanc Biopharma, Inc. (PPCB) announces the validation of PRP dosing and method to treat cancer stem cells patents in countries across Europe, resulting in a growing IP portfolio of 87 patents. The company has achieved grant status for the foundation patent in over 30 different countries across North America, Europe, Asia, the Middle East, and Japan. The PRP dosing patent covers possible future clinical dosage ranges for PRP as the company advances into early stage clinical development. The claims for the CSCs patent cover a method to minimize the progression of cancer in a patient who has already received a first-line treatment by detecting the presence of CSCs, followed by administering PRP. Europe is considered a major global region for pharmaceutical sales, and the company aims to establish itself as a pioneer in novel cancer treatments using proenzyme technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
-
News
Rhea-AI Summary
Propanc Biopharma, Inc. (PPCB) engages boutique advisory firm to identify strategic investment opportunities for advancing cancer treatment PRP and Rec-PRP. PRP shows promising effects against cancer stem cells, offering a less toxic alternative to standard treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.84%
Tags
-
Rhea-AI Summary
Propanc Biopharma, Inc. (OTC Pink: PPCB) is developing novel cancer treatments for recurring and metastatic cancer. The company's joint researcher has commenced an internship at the Cancer Center Amsterdam - vUMC. Preclinical research shows promising results for PRP, a mixture of two proenzymes, as a chemosensitizing agent for resistant tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
76.14%
Tags
Rhea-AI Summary
Propanc Biopharma, Inc. announces that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment, showing potential for combating chemoresistance in pancreatic adenocarcinoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50.79%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.6%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
PROPANC BIOPHARMA INC
OTC:PPCB
PPCB Rankings
PPCB Stock Data
88.65k
52.13M
1.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
Melbourne
About PPCB
propanc biopharma, inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in australia. its lead product is prp, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. the company has a research collaboration with university of jaã©n to commence the pop1 joint drug discovery program. the company was formerly known as propanc health group corporation and changed its name to propanc biopharma, inc. in april 2017. propanc biopharma, inc. was founded in 2007 and is based in camberwell, australia.